{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T02:05:21Z","timestamp":1787623521022,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Korean government","award":["2022R1A2B5B01001216"],"award-info":[{"award-number":["2022R1A2B5B01001216"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-68987-3","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T11:02:03Z","timestamp":1722682923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PET imaging of colon cancer CD73 expression using cysteine site-specific 89Zr-labeled anti-CD73 antibody"],"prefix":"10.1038","volume":"14","author":[{"given":"Kyung-Ho","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Jung","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Lim","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Han","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"10","key":"68987_CR1","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.3390\/cancers11101578","volume":"11","author":"S de Leve","year":"2019","unstructured":"de Leve, S., Wirsd\u00f6rfer, F. & Jendrossek, V. The CD73\/Ado system\u2014A new player in RT induced adverse late effects. Cancers 11(10), 1578. https:\/\/doi.org\/10.3390\/cancers11101578 (2019).","journal-title":"Cancers"},{"issue":"1","key":"68987_CR2","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41467-018-08123-8","volume":"10","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. CD73 expression on effector T cells sustained by TGF-\u03b2 facilitates tumor resistance to anti-4-1BB\/CD137 therapy. Nat. Commun. 10(1), 150. https:\/\/doi.org\/10.1038\/s41467-018-08123-8 (2019).","journal-title":"Nat. Commun."},{"issue":"10","key":"68987_CR3","doi-asserted-by":"publisher","first-page":"3634","DOI":"10.21037\/tcr-22-544","volume":"11","author":"Y Zhou","year":"2022","unstructured":"Zhou, Y. et al. High expression of CD73 contributes to poor prognosis of clear-cell renal cell carcinoma by promoting cell proliferation and migration. Transl. Cancer Res. 11(10), 3634\u20133644. https:\/\/doi.org\/10.21037\/tcr-22-544 (2022).","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"68987_CR4","doi-asserted-by":"publisher","first-page":"6035","DOI":"10.1038\/s41598-021-85379-z","volume":"11","author":"N Petruk","year":"2021","unstructured":"Petruk, N. et al. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer. Sci. Rep, 11(1), 6035. https:\/\/doi.org\/10.1038\/s41598-021-85379-z (2021).","journal-title":"Sci. Rep,"},{"issue":"16","key":"68987_CR5","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"M Nicole","year":"2020","unstructured":"Nicole, M., Anderson, M. & Simon, C. Tumor microenvironment. Curr. Biol. 30(16), R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081 (2020).","journal-title":"Curr. Biol."},{"issue":"12","key":"68987_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nrc.2017.110","volume":"17","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D., Young, A., Teng, M. W. L. & Smyth, M. J. Targeting immunosuppressive adenosine in cancer. Nat. Rev. Cancer 17(12), 709\u2013724. https:\/\/doi.org\/10.1038\/nrc.2017.110 (2017).","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"68987_CR7","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2217\/imt-2018-0200","volume":"11","author":"S Chen","year":"2019","unstructured":"Chen, S. et al. CD73: An emerging checkpoint for cancer immunotherapy. Immunotherapy 11(11), 983\u2013997. https:\/\/doi.org\/10.2217\/imt-2018-0200 (2019) (epub 2019 Jun 21).","journal-title":"Immunotherapy"},{"issue":"12","key":"68987_CR8","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1158\/2159-8290.CD-19-0541","volume":"9","author":"XY Li","year":"2019","unstructured":"Li, X. Y. et al. Targeting CD39 in cancer reveals an extracellular ATP- and inflammasome-driven tumor immunity. Cancer Discov. 9(12), 1754\u20131773. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0541 (2019).","journal-title":"Cancer Discov."},{"issue":"12","key":"68987_CR9","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.3390\/ijms19123837","volume":"19","author":"K Sek","year":"2018","unstructured":"Sek, K. et al. Targeting adenosine receptor signaling in cancer immunotherapy. Int. J. Mol. Sci. 19(12), 3837. https:\/\/doi.org\/10.3390\/ijms19123837 (2018).","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"68987_CR10","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","volume":"186","author":"P Sharma","year":"2023","unstructured":"Sharma, P. et al. Immune checkpoint therapy\u2014Current perspectives and future directions. Cell 186(8), 1652\u20131669. https:\/\/doi.org\/10.1016\/j.cell.2023.03.006 (2023).","journal-title":"Cell"},{"issue":"26","key":"68987_CR11","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443\u20132454. https:\/\/doi.org\/10.1056\/NEJMoa1200690 (2012).","journal-title":"N. Engl. J. Med."},{"issue":"7528","key":"68987_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528), 568\u2013571. https:\/\/doi.org\/10.1038\/nature13954 (2014).","journal-title":"Nature"},{"key":"68987_CR13","doi-asserted-by":"publisher","first-page":"1212209","DOI":"10.3389\/fimmu.2023.1212209","volume":"14","author":"Z Kurago","year":"2023","unstructured":"Kurago, Z. et al. Inhibitors of the CD73-adenosinergic checkpoint as promising combinatory agents for conventional and advanced cancer immunotherapy. Front. Immunol. 14, 1212209. https:\/\/doi.org\/10.3389\/fimmu.2023.1212209 (2023).","journal-title":"Front. Immunol."},{"issue":"20","key":"68987_CR14","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1158\/1078-0432.CCR-13-0545","volume":"19","author":"B Allard","year":"2013","unstructured":"Allard, B., Pommey, S., Smyth, M. J. & Stagg, J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin. Cancer Res. 19(20), 5626\u20135635. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0545 (2013).","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"68987_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1208875","volume":"5","author":"CM Hay","year":"2016","unstructured":"Hay, C. M. et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology 5(8), e1208875. https:\/\/doi.org\/10.1080\/2162402X.2016.1208875 (2016).","journal-title":"Oncoimmunology"},{"issue":"10","key":"68987_CR16","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2967\/jnumed.116.177493","volume":"57","author":"EB Ehlerding","year":"2016","unstructured":"Ehlerding, E. B., England, C. G., McNeel, D. G. & Cai, W. Molecular imaging of immunotherapy targets in cancer. J. Nucl. Med. 57(10), 1487\u20131492. https:\/\/doi.org\/10.2967\/jnumed.116.177493 (2016).","journal-title":"J. Nucl. Med."},{"issue":"11","key":"68987_CR17","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3390\/ijms20112823","volume":"20","author":"B Brodsk\u00e1","year":"2019","unstructured":"Brodsk\u00e1, B. et al. High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations. Int. J. Mol. Sci. 20(11), 2823. https:\/\/doi.org\/10.3390\/ijms20112823 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"68987_CR18","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.3390\/ijms21072304","volume":"21","author":"H Sudo","year":"2020","unstructured":"Sudo, H. et al. Radiolabeled human monoclonal antibody 067-213 has the potential for noninvasive quantification of CD73 expression. Int. J. Mol. Sci. 21(7), 2304. https:\/\/doi.org\/10.3390\/ijms21072304 (2020).","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"68987_CR19","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1021\/acs.molpharmaceut.2c00563","volume":"19","author":"K-H Lee","year":"2022","unstructured":"Lee, K.-H., Jung, K.-H. & Lee, J. H. Immuno-PET imaging and radioimmunotherapy of lymphomas. Mol. Pharm. 19(10), 3484\u20133491. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00563 (2022).","journal-title":"Mol. Pharm."},{"issue":"5","key":"68987_CR20","doi-asserted-by":"publisher","first-page":"656","DOI":"10.2967\/jnumed.120.250720","volume":"62","author":"K-H Jung","year":"2021","unstructured":"Jung, K.-H. et al. 89Zr-labeled anti-PD-L1 antibody PET monitors gemcitabine therapy-induced modulation of tumor PD-L1 expression. J. Nucl. Med. 62(5), 656\u2013664. https:\/\/doi.org\/10.2967\/jnumed.120.250720 (2021).","journal-title":"J. Nucl. Med."},{"issue":"1","key":"68987_CR21","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","volume":"72","author":"T Lindmo","year":"1984","unstructured":"Lindmo, T., Boven, E., Cuttitta, F., Fedorko, J. & Bunn, P. A. Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess. J. Immunol. Methods 72(1), 77\u201389. https:\/\/doi.org\/10.1016\/0022-1759(84)90435-6 (1984).","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"68987_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1312044","volume":"6","author":"D Vijayana","year":"2017","unstructured":"Vijayana, D. et al. Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. Oncoimmunology 6(5), e1312044. https:\/\/doi.org\/10.1080\/2162402X.2017.1312044 (2017).","journal-title":"Oncoimmunology"},{"key":"68987_CR23","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1002\/ijc.28456","volume":"134","author":"B Allard","year":"2014","unstructured":"Allard, B. et al. Anti-CD73 therapy impairs tumor angiogenesis. Int. J. Cancer 134, 1466\u20131473. https:\/\/doi.org\/10.1002\/ijc.28456 (2014).","journal-title":"Int. J. Cancer"},{"issue":"3","key":"68987_CR24","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.immuni.2019.01.010","volume":"50","author":"F Zhang","year":"2019","unstructured":"Zhang, F. et al. Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8+ T cell responses. Immunity 50(3), 738\u2013750. https:\/\/doi.org\/10.1016\/j.immuni.2019.01.010 (2019).","journal-title":"Immunity"},{"issue":"5","key":"68987_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1312044","volume":"6","author":"D Vijayan","year":"2017","unstructured":"Vijayan, D. et al. Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases. Oncoimmunology. 6(5), e1312044 (2017).","journal-title":"Oncoimmunology."},{"issue":"3","key":"68987_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193832","volume":"13","author":"DR Beckford Vera","year":"2023","unstructured":"Beckford Vera, D. R. et al. Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. PLoS ONE 13(3), e0193832 (2023).","journal-title":"PLoS ONE"},{"key":"68987_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41467-019-14060-x","volume":"11","author":"M Yu","year":"2020","unstructured":"Yu, M. et al. CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint. Nat. Commun. 11, 515 (2020).","journal-title":"Nat. Commun."},{"key":"68987_CR28","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1186\/s12885-020-06893-3","volume":"20","author":"H Tsukui","year":"2020","unstructured":"Tsukui, H. et al. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model. BMC Cancer. 20, 411 (2020).","journal-title":"BMC Cancer."},{"key":"68987_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.3390\/cancers13020177","volume":"13","author":"H Yan","year":"2021","unstructured":"Yan, H. et al. CD73, tumor plasticity and immune evasion in solid cancers. Cancers 13, 177 (2021).","journal-title":"Cancers"},{"key":"68987_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","volume":"53","author":"M Roh","year":"2020","unstructured":"Roh, M. et al. Targeting CD73 to augment cancer immunotherapy. Curr. Opin. Pharmacol. 53, 66\u201376 (2020).","journal-title":"Curr. Opin. Pharmacol."},{"issue":"3","key":"68987_CR31","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1007\/s00262-018-2290-1","volume":"68","author":"A Sciarra","year":"2019","unstructured":"Sciarra, A. et al. CD73 expression in normal and pathological human hepatobiliopancreatic tissues. Cancer Immunol. Immunother. 68(3), 467\u2013478 (2019).","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"68987_CR32","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jcmgh.2021.01.016","volume":"12","author":"KP Alcedo","year":"2021","unstructured":"Alcedo, K. P. et al. CD73 maintains hepatocyte metabolic integrity and mouse liver homeostasis in a sex-dependent manner. Cell Mol. Gastroenterol. Hepatol. 12(1), 141\u2013157 (2021).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"issue":"1","key":"68987_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol. Rev. 276(1), 121\u2013144 (2017).","journal-title":"Immunol. Rev."},{"issue":"2","key":"68987_CR34","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s00428-020-02888-4","volume":"478","author":"K Tahkola","year":"2021","unstructured":"Tahkola, K. et al. Prognostic impact of CD73 expression and its relationship to PD-L1 in patients with radically treated pancreatic cancer. Virchows Arch. 478(2), 209\u2013217. https:\/\/doi.org\/10.1007\/s00428-020-02888-4 (2021).","journal-title":"Virchows Arch."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68987-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T11:04:02Z","timestamp":1722683042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-68987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["68987"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-68987-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"15 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17994"}}